A first-in-human study of FT516 to evaluate the safety and tolerability of multiple dosing cycles of FT516 in combination with FDA-approved monoclonal antibody therapy.

Trial Profile

A first-in-human study of FT516 to evaluate the safety and tolerability of multiple dosing cycles of FT516 in combination with FDA-approved monoclonal antibody therapy.

Planning
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs FT-516 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top